Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 762 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Preparación para el fin de la emergencia de salud pública (PHE)... April 3, 2023 New on NCI’s Websites for March 2019 March 29, 2019 Cancer Patient’s Appetite Increases And His Blood Pressure Lowers After A... September 24, 2019 Discovery of Tumor Suppressor Suggests New Cancer Treatment Strategies May 14, 2021 Load more HOT NEWS What to Know About Using Activated Charcoal During Cancer FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection Studies Delve Deep into the Protein Machinery of Cancer Cells High Risk of BCSM at 20 Years in Men with Hormone...
